key: cord-0962636-vgkpo4qm authors: Sampath U. Gunathilake, Thennakoon M.; Ching, Yern Chee; Uyama, Hiroshi; Chuah, Cheng Hock title: Nanotherapeutics for treating coronavirus diseases date: 2021-06-10 journal: J Drug Deliv Sci Technol DOI: 10.1016/j.jddst.2021.102634 sha: a48fd765f3f9746e05fba890d3589a3eddc844a4 doc_id: 962636 cord_uid: vgkpo4qm Viral diseases have recently become a threat to human health and rapidly become a significant cause of mortality with a continually exacerbated unfavorable socio-economic impact. Coronaviruses, including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome (MERS-CoV), and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), have threatened human life, with immense accompanying morbidity rates; the COVID-19 (caused by SARS-CoV-2) epidemic has become a severe threat to global public health. In addition, the design process of antiviral medications usually takes years before the treatments can be made readily available. Hence, it is necessary to invest scientifically and financially in a technology platform that can then be quickly repurposed on demand to be adequately positioned for this kind of pandemic situation through lessons learned from the previous pandemics. Nanomaterials/nanoformulations provide such platform technologies, and a proper investigation into their basic science and biological interactions would be of great benefit for potential vaccine and therapeutic development. In this respect, intelligent and advanced nano-based technologies provide specific physico-chemical properties, which can help fix the key issues related to the treatments of viral infections. This review aims to provide an overview of the latest research on the effective use of nanomaterials in the treatment of coronaviruses. Also raised are the problems, perspectives of antiviral nanoformulations, and the possibility of using nanomaterials effectively against current pandemic situations. Viral infections can pose a considerable threat to human health due to their troublesome 35 widespread distribution and their ability to adapt through genetic mutations. The large number of 36 fatalities caused by such infections has also become a huge concern for healthcare systems over 37 the past few decades [1, 2] . Despite tremendous scientific advancements, human beings immunization with DNA [12] . However, it is not possible to ignore health issues regarding DNA 134 vaccines, their inadequate induction of neutralizing antibodies, and the possibility for decreased 135 efficiency of viral vector vaccines due to pre-existing viral vector immunity triggered by 136 repeated immunization. Although protein subunit vaccines can provoke the neutralizing 137 antibodies, the induction of cellular immune responses is relatively poor. In addition, subunit 138 vaccines have not been able to induce adequate host immune responses, which resulted in a lack 139 of long-lasting memory to an antigen [35] . 140 J o u r n a l P r e -p r o o f Not unsurprisingly, in the fields of vaccine research and manufacturing, emerging approaches 141 that overcome such limits are a high priority. Virus-like particles (VLPs), nanoparticles (NPs), 142 and multimeric peptide assemblies offer attractive platforms for the development of vaccines 143 [36]. Attention should be paid to choosing a stable and reliable NP assembly system to produce 144 NP vaccines that encourage cost-effective production and timely delivery of vaccines. In scaffold for expressing the antigens of concern instead of the lipid membranes [45, 46] . 162 J o u r n a l P r e -p r o o f Lin, et al. [47] prepared hollow polymeric (poly(lactic-co-glycolic acid)) nanoparticles to deliver 163 subunit antigens (MERS-CoV) and adjuvant (STING agonists) in a virus-like manner to enhance 164 the effectiveness of the vaccine (Fig. 1A) . The water-in-oil-in-water double emulsion method 165 was used to prepare the hollow polymeric nanoparticles. 166 The free cyclic di-guanosinemonophosphate (cdGMP-STING agonists) rapidly diffused into the immunogen is the S1 subunit protein, bound to the membrane by interaction with the S2 subunit, 236 which is involved in viral entry and produces epitopes that induce the production of potent New IB vaccine formulations are widely attempted to address the shortcomings described above. obtained using the Bac-to-Bac baculovirus expression system. The spontaneous association of 277 antigen-particle was obtained by mixing purified spike proteins with gold nanoparticles in 10% 278 sucrose and optimized incubation conditions (Fig. 1B) . The size of the nanoparticle increased 279 from 100.6 nm to 139.2 nm with protein corona formation. Results showed that antigen delivery increased by 6-fold with sVLPs compared to the free 281 protein formulation. This was due to the strong adhesion of protein/particle on the nanoparticle 282 surface and the facilitation of in vivo antigen transport by particle carrier. In addition, sVLPs After that, the centrifugation step was followed to precipitate IBV-CS. The encapsulation 299 efficiency was around 85%, and the size of the spherical-shaped nanoparticles was 286 nm. Spodoptera frugiperda9 (Sf9) cells. The S proteins were extracted from cell membranes using a 381 non-ionic detergent, and the centrifugation step was followed to remove the insoluble materials. The combination of anion exchange, affinity, and size exclusion chromatography was used to 383 purify the S proteins oligomers. The detergent's remainder is removed during the purification 384 step, enabling the S trimers to assemble higher-ordered micellular protein-protein nanoparticles. For humans, the SARS vaccine strategy using full-length S protein may not be the best choice. 438 Therefore, the best approach will be to use small epitopes of S proteins, which are essential with the highest total number of confirmed cases [92] . It has been shown that the mortality from 468 this pandemic varies from 1 to more than 7 percent. The main concern is the transmissibility of 469 this virus, which contributes to increased infection rates as it spreads at a rate of 0.8-3 percent It usually takes years before treatments can be made readily available for the design phase of 492 antiviral medicines as there is a range of regulatory procedures that are needed to assess the 493 safety and effectiveness of vaccines and drugs. Furthermore, when SARS-CoV-2 continues to 494 mutate, highly specific viral targets may change, leading to drug resistance, as observed. 2) S protein encapsulated lipid nanoparticle (LNP)s to the body's immune response produced by 520 a COVID-19 recovered patient (Fig. 6) . A self-assembly method was used to encapsulate shown when those enzymes were coated on specified nanoparticles. Therefore, using 558 nanomaterials, ACE2-coated/embedded stable quantum dots or nanoflowers can be synthesized 559 with the improved catalytic activity of ACE2 and used to manufacture masks, gloves, chewing 560 gums, nose filters, and garments. These facts propose that such viruses will be captured by 561 utilizing nanotechnology in products such as masks, clothes, chewing gums, gloves, etc., before 562 reaching the host. Allergens and pollens are caught by nose filters before they reach the host. Like nasal filters, ACE2-coated nanoparticle contained chewing gums, clothes, filters, and 564 gloves may trap and hold viruses before they reach the host. are unable to digest food properly and die due to dehydration. The mortality rate can be greater 687 than 90% and is inversely proportional to the pig's age [112] . Not like other porcine enteric Table 1 . Significantly enhanced the protection and effectiveness of diphyllin, raised the therapeutic index by approximately 800, showed a 13-fold decrease in cellular toxicity, showed a 60-fold increase in antiviral activity, well tolerated after intravenous administration. [130] Graphene oxide sheets with silver particles (antiviral activity) The GO sheets were synthesized using Hummers process. GO powders were dispersed in AgNO 3 and ethylene glycol. To enhance antiviral action Showed concentration-dependent inhibition behavior of FCoV To enhance antiviral action Showed reduced cytotoxicity, showed significantly enhanced viral inhibitory effects, showed enhanced anti-inflammatory activities and bioavailability properties. Other NP-related toxicity concerns involve accumulation in cells, primarily due to prolonged 986 exposure or long-term usage. For example, fluorescent quantum dots were detected in mice 2 987 years after injection [139] . In general, the approaches used to detect NP trafficking in cells are 988 mostly based on pharmacological inhibitors or mutant cell lines. The concern with these analyses 989 is that these techniques are not unique to one trafficking mechanism, and therefore findings may 990 also be challenging to interpret or even contradict other literature. For example, while Rejman, et 991 al. [140] reported that the treatment of B16 cells with chlorpromazine strongly decreased the Emerging/re-emerging viral diseases & new viruses on the Indian horizon The consequences of human actions on risks for infectious diseases: a review Infectious diseases-past, present, and future The challenge of emerging and re-emerging infectious 1107 diseases Nanoparticle-based vaccines against 1109 respiratory viruses Respiratory tract viral infections Respiratory viruses, Encyclopedia of Microbiology Respiratory viruses other than influenza virus: impact and 1114 therapeutic advances Respiratory 1116 viruses: influenza virus, respiratory syncytial virus, human metapneumovirus, parainfluenza viruses, 1117 rhinovirus, respiratory adenoviruses, Coronaviruses (unrelated to SARS) and human bocavirus Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques Fenner and White's Medical Virology Animal coronaviruses in the light of COVID-19 Severe acute respiratory syndrome Coronavirus-2 (SARS-1127 CoV-2): An update Impact of coronavirus outbreak 1129 on psychological health Severe acute respiratory syndrome coronavirus as an 1131 agent of emerging and reemerging infection The outbreak of the novel severe acute respiratory 1133 syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status Current status of potential therapeutic candidates for the COVID-19 1136 crisis Vaccines and antiviral agents, Current Issues in Molecular Virology: Viral Genetics and 1138 Biotechnological Applications Repurposing drugs, ongoing vaccine and new therapeutic development initiatives against 1141 COVID-19 Current global vaccine and drug efforts against COVID-19: Pros and cons of 1143 bypassing animal trials Drug targets for COVID-19 therapeutics: Ongoing global efforts Engineered nanomaterials for pharmaceutical and biomedical 1147 products new trends, benefits and opportunities Smart nanoparticles for drug delivery application: 1149 development of versatile nanocarrier platforms in biotechnology and nanomedicine Current trends and 1152 challenges in cancer management and therapy using designer nanomaterials Nanotechnology-based antiviral therapeutics Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic Novel adjuvants & delivery vehicles for vaccines development: a road 1160 ahead Distinction between active 1162 and passive targeting of nanoparticles dictate their overall therapeutic efficacy Cancer active targeting by nanoparticles: a 1165 comprehensive review of literature Passive targeting of nanoparticles to cancer: A 1167 comprehensive review of the literature Isolation of a novel 1169 coronavirus from a man with pneumonia in Saudi Arabia Treatment strategies for Middle East respiratory syndrome coronavirus Middle east respiratory syndrome coronavirus (MERS-CoV): 1174 infection, immunological response, and vaccine development Peptide vaccines against cancer, infectious diseases, and conception, Front Vaccine delivery using nanoparticles Comparative protein structure modeling using MODELLER Structure-based design of peptides that 1182 self-assemble into regular polyhedral nanoparticles Comparative protein structure 1184 modeling of genes and genomes Vaccine delivery: a matter of size, geometry, kinetics and molecular 1186 patterns Virus-like particles as a highly efficient vaccine platform: 1188 diversity of targets and production systems and advances in clinical development The influence 1191 of antigen organization on B cell responsiveness Structure of the hepatitis E virus-like 1193 particle suggests mechanisms for virus assembly and receptor binding Self-assembly of human papillomavirus type 1 capsids by 1196 expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins Chaperna-1199 mediated assembly of ferritin-based Middle East respiratory syndrome-coronavirus nanoparticles, Front. 1200 Immunol Virus-like particles as universal influenza vaccines Viromimetic STING Agonist-Loaded Hollow Polymeric Nanoparticles for Safe and Effective 1205 Vaccination against Middle East Respiratory Syndrome Coronavirus Block copolymer 1208 crystalsomes with an ultrathin shell to extend blood circulation time Polymersomes: 1210 tough vesicles made from diblock copolymers Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both 1213 Th1 and Th2 responses against Middle East respiratory syndrome coronavirus An apparently new respiratory disease of baby chicks Order of exposure to high dietary calcium and Gray 1218 strain infectious bronchitis virus alters renal function and the incidence of urolithiasis Infectious bronchitis, Diseases of poultry The long view: 40 years of infectious bronchitis research Incorporation of spike and membrane glycoproteins into coronavirus virions Avian infectious bronchitis virus in Africa: a review Antigenic domains on the peplomer protein of avian 1228 infectious bronchitis virus: correlation with biological functions The S1 glycoprotein but not the N or M proteins of avian infectious bronchitis 1230 virus induces protection in vaccinated chickens Bronchitis Virus Pathogenesis, Diagnostic Approaches, and Phylogenetic Relationship Among Emerging 1233 Emerging and Reemerging Viral Pathogens Review of infectious bronchitis virus around the world Infectious bronchitis virus variants: a review of the 1238 history, current situation and control measures Vaccination against infectious bronchitis virus: a continuous challenge Infectious bronchitis virus in 1242 different avian physiological systems-a field study in Brazilian poultry flocks Nephritis associated with a S1 1246 variant brazilian isolate of infectious bronchitis virus and vaccine protection test in experimentally 1247 infected chickens Assessment of molecular and genetic 1250 evolution, antigenicity and virulence properties during the persistence of the infectious bronchitis virus 1251 in broiler breeders Increased level of protection of 1253 respiratory tract and kidney by combining different infectious bronchitis virus vaccines against challenge 1254 with nephropathogenic Brazilian genotype subcluster 4 strains Progress and challenges toward the 1256 development of vaccines against avian infectious bronchitis Etiology and immunology of infectious bronchitis virus Immune responses to virulent and vaccine strains of 1260 infectious bronchitis viruses in chickens 1262 Synthetic virus-like particles prepared via protein corona formation enable effective vaccination in an 1263 avian model of coronavirus infection Inactivated infectious bronchitis virus vaccine encapsulated in chitosan nanoparticles 1266 induces mucosal immune responses and effective protection against challenge Quaternized chitosan nanoparticles 1269 loaded with the combined attenuated live vaccine against Newcastle disease and infectious bronchitis 1270 elicit immune response in chicken after intranasal administration Development 1272 of a SARS coronavirus vaccine from recombinant spike protein plus delta inulin adjuvant SARS vaccine development Intranasal immunization with plasmid DNA encoding spike protein of SARS-1277 coronavirus/polyethylenimine nanoparticles elicits antigen-specific humoral and cellular immune 1278 responses 1280 Couch, Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on 1281 challenge with the SARS virus A recombinant baculovirus-1283 expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) 1284 neutralizing antibodies in mice Structural 1286 characterization of the SARS-coronavirus spike S fusion protein core Characterization of the 1289 prefusion and transition states of severe acute respiratory syndrome coronavirus S2-HR2 Crystal structure of severe acute respiratory 1292 syndrome coronavirus spike protein fusion core A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates 1295 neutralising and protective antibody responses Immunogenicity 1297 and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine Safety and 1300 immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus 1301 vaccine A double-inactivated severe acute respiratory syndrome coronavirus vaccine 1304 provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary 1305 response upon challenge Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG 1308 response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce 1309 protective antibodies and limit eosinophilic infiltration in lungs Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in 1312 mice Induction of gp120-specific protective immune responses by genetic 1315 vaccination with linear polyethylenimine-plasmid complex Dendritic cell targeted chitosan 1317 nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein Peptide nanoparticles as 1320 novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine Hydroxychloroquine and Azithromycin as a treatment of COVID-19: 1323 preliminary results of an open-label non-randomized clinical trial of the International, The species Severe acute respiratory syndrome-related coronavirus: 1325 classifying 2019-nCoV and naming it SARS-CoV-2 Can the coronavirus disease 2019 (COVID-19) affect the eyes? A review of 1327 coronaviruses and ocular implications in humans and animals IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy? Clinical presentation of COVID-19: a systematic review focusing on upper 1332 airway symptoms Cardiovascular disease and COVID-19 Nervous system involvement 1336 after infection with COVID-19 and other coronaviruses The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: 1339 estimation and application DRAFT landscape of COVID-19 candidate vaccines Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing 1343 antibody titers in mice Outfitting COVID-19: An Effective Therapeutic Approach: Targeted Therapy of COVID-1345 19 Formulations for COVID-19 Early Stage Treatment via Silver Nanoparticles Inhalation 1347 Delivery at Home and Hospital Silver Nanoparticles with Bronchodilators Through Nebulisation to Treat COVID 19 1349 Patients Correspondence: Angiotensin-converting enzyme 2 coated nanoparticles 1351 containing respiratory masks, chewing gums and nasal filters may be used for protection against COVID-1352 19 infection Can graphene take part in the fight against COVID-19? Herpes simplex virus type-1 attachment inhibition by 1356 functionalized graphene oxide Graphene o ide and lipid mem ranes 1358 interactions and nanocomposite structures Repurposing therapeutics for COVID-19: Supercomputer-based docking to 1360 the SARS-CoV-2 viral spike protein and viral spike protein-human ACE2 interface Screen printed graphene oxide textile 1362 biosensor for applications in inexpensive and wearable point-of-exposure detection of influenza for at-1363 risk populations Vaccine Development -101, in, U.S. Food and Drug Administration Vaccines through centuries: major cornerstones of global health, Frontiers in public health Transmissible gastroenteritis virus (TGEV) 1371 infection alters the expression of cellular microRNA species that affect transcription of TGEV gene 7, Int. 1372 Rapid and efficient detection methods of pathogenic swine enteric 1374 coronaviruses Nanoparticle-based vaccine development and evaluation against 1376 viral infections in pigs Inhibitory effect of silver nanomaterials on 1378 transmissible virus-induced host cell infections Prospects for the use of spherical gold nanoparticles in immunization Study of immunogenic properties of transmissible gastroenteritis virus antigen conjugated 1384 to gold nanoparticles A nano silicon adjuvant enhances inactivated transmissible gastroenteritis vaccine through 1387 activation the Toll-like receptors and promotes humoral and cellular immune responses Deadly pig virus slips through US borders Targeting of phospho-eIF4E by homoharringtonine 1391 eradicates a distinct subset of human acute myeloid leukemia The natural compound 1393 homoharringtonine presents broad antiviral activity in vitro and in vivo Three kinds of treatment with Homoharringtonine, Hydroxychloroquine or 1395 shRNA and their combination against coronavirus PEDV in vitro Glutathione-capped Ag2S nanoclusters 1397 inhibit coronavirus proliferation through blockage of viral RNA synthesis and budding Multisite inhibitors for enteric coronavirus: 1400 antiviral cationic carbon dots based on curcumin Poly (d, l-lactide-co-glycolide) 1402 nanoparticle-entrapped vaccine induces a protective immune response against porcine epidemic 1403 diarrhea virus infection in piglets Family Coronaviridae, Viruses A tale of two viruses: the distinct 1406 spike glycoproteins of feline coronaviruses Vaccine efficacy of a cell lysate with recombinant baculovirus-expressed feline infectious 1409 peritonitis (FIP) virus nucleocapsid protein against progression of FIP Encapsulated Chitosan Nanoparticles against Feline Infectious Peritonitis Virus and Pharmacokinetics 1412 Study in Cats Nanoparticulate vacuolar ATPase blocker exhibits potent host-targeted antiviral 1415 activity against feline coronavirus Antiviral Activity of Graphene-Silver 1417 Nanocomposites against Non-Enveloped and Enveloped Viruses The role of nanotechnology in the 1420 treatment of viral infections Intranasal 1422 nanovaccine confers homo-and hetero-su typic influenza protection Chitosan nanoparticle 1424 encapsulated hemagglutinin-split influenza virus mucosal vaccine Intranasal immunisation of mice 1427 against Streptococcus equi using positively charged nanoparticulate carrier systems Plasmid DNA loaded chitosan nanoparticles 1430 for nasal mucosal immunization against hepatitis B Titanium Dioxide Nanoparticles 1432 in Food and Personal Care Products-What Do We Know about Their Safety? Effect of size on biological properties of 1435 nanoparticles employed in gene delivery Long-term 1437 persistence and spectral blue shifting of quantum dots in vivo Size-dependent internalization of particles via the 1439 pathways of clathrin-and caveolae-mediated endocytosis Effects of transport inhibitors on the 1441 cellular uptake of carboxylated polystyrene nanoparticles in different cell lines Immobilization of lysozyme-cellulose 1444 amide-linked conjugates on cellulose I and II cotton nanocrystalline preparations Tryptophan-based peptides grafted onto oxidized nanocellulose Immo ilization-stabilization of proteins on 1449 nanofibrillated cellulose derivatives and their bioactive film formation Bionanocomposites: differential effects of cellulose nanocrystals on protein diblock 1453 copolymers Adsorption and hydrolytic activity of trypsin on a carboxylate-1455 functionalized cation exchanger prepared from nanocellulose Applications of nanomaterials as vaccine adjuvants The authors would like to acknowledge the financial support from the AUN/SEED-Net Special 1097 Program for Research Against COVID-19 (SPRAC): IF068-2020 for the success of this project. 1098 nanoparticles to treat COVID-19 at an early stage through inhalation. As a first-line 1006 treatment to inhibit the progression of the disease, a model and computation method for 1007 generating antiviral minimum inhibitory concentrations of silver particles in various 1008 respiratory system locations was proposed [101] . Besides the metal nanoparticles, 1009 bionanoparticles (e.g., nanocelluloses) carrying synthetic antiviral drugs or herbal 1010 antiviral drugs (e.g., curcumin) can also be suggested to treat COVID-19 at an early stage 1011 through inhalation.  Designing a noninvasive nanoparticle vaccine delivery system by targeting vaccine 1013 antigens to provide antigen-specific mucosal immunity can be used as an important 1014 approach to treat COVID-19. The respiratory tract holds a subset of local dendritic cells, 1015 which regularly sample and process innocuous agents. Therefore, dendritic cells of the 1016 respiratory tract could act as an ideal target for the absorption of specific NPs delivered 1017 along a non-invasive route to treat COVID-19. In previous studies, Raghuwanshi, et al. [88] developed a successful approach for enhancing the immunogenicity of low-dose 1019 DNA vaccine through targeted delivery to nasal resident dendritic cells. This vaccine 1020 approach provides a new insight for non-invasive ways of targeting vaccine antigens to 1021 dendritic cells.  Though there are many COVID-19 vaccines that have been produced all around the 1023 world; still, tens of thousands of people will need to be enrolled to confirm the 1024 effectiveness and to look for long-term side effects. Among several approaches to 1025 designing vaccines, one concern is that some vaccines can protect against disease but not